As the experimental blockade of C5a and C5aR1 has been shown to result in an improved sepsis outcome [30], therapeutic targets of the complement system in human sepsis therapy are the focus of current research [66] and seem to be a promising approach. The gene discussed is C5AR1; the disease is Sepsis.